A Phase 1/2 Study of REGN4018 (A MUC16×CD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
ENROLLING
Trial ID:
NCT03564340 Protocol # :
18-227
Phase
I/II
Disease Sites
Corpus Uteri
Ovary
Principal Investigator
Liu, Joyce, F
Site Investigator
Spriggs, David, R.
Yeku, Oladapo, O.
Site Research Nurses
Belavusava, Vera
Bowes, Brittany, N.
Colella, Tina
Doherty, Kelsie
Furtado, Mollie, E.
Geary, Molly
Hindenach, Sarah
Hurley-Whalen, Christin
Keis, Rylee
Markt, Denise, A.
Morrissey, Stephanie, C.
Neals, Allison
Weitz, MaryAnn
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #18-227
18-227